CA2353693A1 - Pharmaceutical composition containing citalopram - Google Patents

Pharmaceutical composition containing citalopram Download PDF

Info

Publication number
CA2353693A1
CA2353693A1 CA002353693A CA2353693A CA2353693A1 CA 2353693 A1 CA2353693 A1 CA 2353693A1 CA 002353693 A CA002353693 A CA 002353693A CA 2353693 A CA2353693 A CA 2353693A CA 2353693 A1 CA2353693 A1 CA 2353693A1
Authority
CA
Canada
Prior art keywords
citalopram
pharmaceutical composition
composition containing
containing citalopram
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002353693A
Other languages
French (fr)
Other versions
CA2353693C (en
Inventor
Ken Liljegren
Per Holm
Ole Nielsen
Sven Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H. Lundbeck A/S
Ken Liljegren
Per Holm
Ole Nielsen
Sven Wagner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26068858&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2353693(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S, Ken Liljegren, Per Holm, Ole Nielsen, Sven Wagner filed Critical H. Lundbeck A/S
Publication of CA2353693A1 publication Critical patent/CA2353693A1/en
Application granted granted Critical
Publication of CA2353693C publication Critical patent/CA2353693C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A solid unit dosage form comprising citalopram, which is prepared by direct compression of a mixture of citalopram base or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, or by filling of said mixture in a hard gelatine capsule. Large crystals of a pharmaceutical acceptable salt of citalopram and method for the manufacture of said large crystals.
CA002353693A 2000-08-10 2001-07-24 Pharmaceutical composition containing citalopram Expired - Lifetime CA2353693C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200001202 2000-08-10
DKPA200001202 2000-08-10
DKPA200001614 2000-10-27
DKPA200001614 2000-10-27

Publications (2)

Publication Number Publication Date
CA2353693A1 true CA2353693A1 (en) 2002-01-22
CA2353693C CA2353693C (en) 2003-07-22

Family

ID=26068858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002353693A Expired - Lifetime CA2353693C (en) 2000-08-10 2001-07-24 Pharmaceutical composition containing citalopram

Country Status (34)

Country Link
EP (1) EP1318805A2 (en)
JP (1) JP2003531153A (en)
KR (1) KR20030024833A (en)
CN (1) CN1446089A (en)
AR (1) AR030095A1 (en)
AT (1) AT5744U1 (en)
AU (2) AU2001100198B4 (en)
BE (1) BE1013559A6 (en)
BG (1) BG107578A (en)
BR (1) BR0113250A (en)
CA (1) CA2353693C (en)
CH (2) CH694241A5 (en)
CZ (1) CZ2003397A3 (en)
DE (2) DE10139115A1 (en)
EA (1) EA200300247A1 (en)
ES (1) ES2172481B2 (en)
FI (1) FI5176U1 (en)
FR (1) FR2812811B1 (en)
GB (1) GB2368014B (en)
GR (1) GR1004193B (en)
HR (1) HRP20030054A2 (en)
HU (1) HUP0103071A3 (en)
IE (1) IES20010693A2 (en)
IL (1) IL154050A0 (en)
IS (1) IS6021A (en)
IT (1) ITMI20011637A1 (en)
MX (1) MXPA03000837A (en)
NL (1) NL1018741C1 (en)
NO (1) NO20013891L (en)
NZ (1) NZ523785A (en)
PL (1) PL359824A1 (en)
SK (1) SK2842003A3 (en)
WO (1) WO2001080619A2 (en)
YU (1) YU9003A (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2353693C (en) * 2000-08-10 2003-07-22 H. Lundbeck A/S Pharmaceutical composition containing citalopram
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
GB0206708D0 (en) * 2002-03-21 2002-05-01 Cipla Ltd Pharmaceutical salts
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
RS51092B (en) * 2002-12-23 2010-10-31 H. Lundbeck A/S. Escitalopram hydrobromide and a method for the preparation thereof
WO2004103361A2 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited A pharmaceutical dosage form of citalopram
HU227491B1 (en) * 2003-11-25 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Tablet containing citalopram hydrogen bromide
WO2006038217A1 (en) * 2004-10-05 2006-04-13 Strides Acrolab Limited An improved drug delivery system of citalopram hydrobromide and process for producing the same
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
CN100353939C (en) * 2006-01-05 2007-12-12 昆明积大制药有限公司 Antidepressant composition containing citalopram and cyclodextrin
GB2446847B (en) * 2007-02-02 2012-02-22 Ubiquisys Ltd Location of Basestation
CN106389374A (en) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 Pharmaceutical composition containing LCZ696 and preparation method of pharmaceutical composition
US20240100012A1 (en) * 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1358915A (en) * 1919-04-14 1920-11-16 Amici Domenico Aeroplane
GB1358915A (en) * 1971-09-13 1974-07-03 Merck & Co Inc Directly compressed tablet and composition therefor
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug response by a serotonin 1A receptor antagonist
GB9714841D0 (en) * 1997-07-14 1997-09-17 Smithkline Beecham Plc Treatment method
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
CA2353693C (en) * 2000-08-10 2003-07-22 H. Lundbeck A/S Pharmaceutical composition containing citalopram

Also Published As

Publication number Publication date
CH694242A5 (en) 2004-10-15
BR0113250A (en) 2003-06-24
ES2172481B2 (en) 2004-08-01
GB0118579D0 (en) 2001-09-19
EP1318805A2 (en) 2003-06-18
IS6021A (en) 2001-10-20
HRP20030054A2 (en) 2005-02-28
AU2001100198B4 (en) 2002-06-13
CH694241A5 (en) 2004-10-15
HUP0103071A2 (en) 2002-05-29
AU2001279591A1 (en) 2001-11-07
DE20113195U1 (en) 2001-11-15
NL1018741C1 (en) 2002-02-12
PL359824A1 (en) 2004-09-06
FR2812811B1 (en) 2006-08-18
GR20010100377A (en) 2002-09-06
FR2812811A1 (en) 2002-02-15
CN1446089A (en) 2003-10-01
IL154050A0 (en) 2003-07-31
GR1004193B (en) 2003-03-24
NZ523785A (en) 2004-09-24
GB2368014A (en) 2002-04-24
ITMI20011637A1 (en) 2003-01-27
ITMI20011637A0 (en) 2001-07-27
NO20013891D0 (en) 2001-08-09
FI5176U1 (en) 2001-12-27
CZ2003397A3 (en) 2003-06-18
HU0103071D0 (en) 2001-10-28
ES2172481A1 (en) 2002-09-16
AT5744U1 (en) 2002-11-25
WO2001080619A2 (en) 2001-11-01
SK2842003A3 (en) 2003-09-11
EA200300247A1 (en) 2003-06-26
AR030095A1 (en) 2003-08-13
BE1013559A6 (en) 2002-03-05
BG107578A (en) 2003-09-30
MXPA03000837A (en) 2003-06-06
AU2001100198A4 (en) 2001-08-16
GB2368014B (en) 2004-06-23
DE10139115A1 (en) 2002-03-28
WO2001080619A3 (en) 2002-02-21
JP2003531153A (en) 2003-10-21
HUP0103071A3 (en) 2002-12-28
YU9003A (en) 2006-05-25
IES20010693A2 (en) 2002-07-10
NO20013891L (en) 2002-02-11
KR20030024833A (en) 2003-03-26
CA2353693C (en) 2003-07-22

Similar Documents

Publication Publication Date Title
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
CA2382098A1 (en) Sustained-release, oral pharmaceutical forms of administration
CA2353693A1 (en) Pharmaceutical composition containing citalopram
AU6136199A (en) Dosage form comprising therapeutic formulation
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
RU2003116058A (en) COMPOSITIONS OF A HYDROCODON WITH CONTROLLED RELEASE
DE69620606T2 (en) FIXED ORAL APPLICATION FORM
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
CA2182004C (en) Film coated tablet of paracetamol and domperidone
RU2003100507A (en) PHARMACEUTICAL COMPOSITIONS
HUP0301390A2 (en) Oral pharmaceutical composition containing valsartan
CA2366841A1 (en) Tolperisone-containing pharmaceutical preparation for oral administration
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
HRP20000291B1 (en) High purity (1r, 2s, 4r)-(-)-2-/(2'-/n,n-dimethylamino/-ethoxy)/-2-/phenyl/-1,7,7-tri-/methyl/bicyclo/2.2.1/ heptane and pharmaceutically acceptable acid addition salts thereof and process for the preparation of these compounds as well medicaments containing one or more of them and the use thereof
JP2005525391A5 (en)
YU54503A (en) Pharmaceutical composition containing citalopram
WO2005004836A3 (en) Saquinavir mesylate oral dosage form
EA200101108A1 (en) POLYMORPHIC MODIFICATIONS OF AZABICYCLO [2.2.2] OKTAN-3-AMINE AND THEIR PHARMACEUTICAL COMPOSITIONS
CA2423288A1 (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
RU2002126216A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF LIVER FIBROSIS AND CIRROSIS
HUP0401912A3 (en) Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them
KR910004181A (en) New Pharmaceutical Oral Dosage Forms That Increase In Vivo Effectiveness
ATE303136T1 (en) ANHYDROUS DOUBLE-COATED TABLET CONTAINING RANITIDINE HYDROCHLORIDE AND COMPOSITION THEREOF
CA2214923A1 (en) Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210726